<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548690</url>
  </required_header>
  <id_info>
    <org_study_id>ALFSG-OCR-002</org_study_id>
    <secondary_id>U01DK058369</secondary_id>
    <nct_id>NCT01548690</nct_id>
  </id_info>
  <brief_title>Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure</brief_title>
  <acronym>STOP-ALF</acronym>
  <official_title>A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ocera Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2a clinical study is designed to provide data on OCR-002 in patients with acute
      liver failure/acute liver injury (ALF/ALI) in regard to:

        -  safety and tolerability;

        -  metabolism of the compound to glutamine and phenylacetylglutamine (PAGN);

        -  its effect on circulating ammonia levels and neurological function in patients with and
           without impaired renal function after continuous infusion at different infusion rates.

      Subjects will receive up to 120 hours (5 days) of drug infusion, followed by a 30 day
      follow-up visit post infusion. It is anticipated that this early safety and tolerability
      study, with appropriate PK/PD data, will lead to a development program for the use of OCR-002
      in the treatment of hyperammonemia either due to ALF or possibly other liver conditions. The
      hypotheses are:

        -  Treatment with OCR-002 is safe and tolerable in patients with acute liver failure/acute
           liver injury due to acetaminophen overdose or drug-induced liver injury, autoimmune
           hepatitis, viral hepatitis or indeterminate etiologies.

        -  A dose of 10-20g/24h (0.42-.83g/h) will achieve steady state plasma concentrations
           within 6-12h with little additional accumulation in the ALI/ALF setting.

        -  Treatment with OCR-002 will reduce ammonia and improve neurological function in patients
           with acute liver failure/severe acute liver injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is strong experimental and clinical rationale for the use of ammonia-lowering therapies
      in ALF. Ammonia is normally produced in the gut and transformed by the liver into urea. As
      the liver fails, ammonia increases in the systemic circulation and enters into the brain. The
      result of a rapid rise in ammonia or related compounds in the cerebral circulation is hepatic
      encephalopathy (HE), a reversible neuropsychiatric condition that ranges in severity from
      mild impairment in attention, to delirium, the development of cerebral edema, coma and death.
      This is a Phase 2a, multi-center, open-label study, conducted in two cohorts in patients
      diagnosed with acute liver failure/acute liver injury (ALF/ALI) who meet inclusion/exclusion
      criteria. This study is designed to provide data on OCR-002 with regards to

        -  the effect on circulating ammonia levels in patients with acute liver failure with and
           without impaired renal function at different doses after single and continuous infusion

        -  safety and dose tolerability as well as

        -  providing data on the metabolites, glutamine and phenylacetylglutamine in this patient
           population.

      It is anticipated that this early efficacy, safety, tolerability,
      Pharmacokinetic/Pharmacodynamic (PK/PD) and dose-ranging study will lead to a Phase 3
      development program for the use of OCR-002 in the treatment of hyperammonemia due to ALF. No
      clinical outcome measures will be formally studied because of the small sample size.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 23, 2017</completion_date>
  <primary_completion_date type="Actual">February 23, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>30 Days</time_frame>
    <description>To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of OCR-002 Plasma Concentration</measure>
    <time_frame>30 days</time_frame>
    <description>To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary PAGN as a surrogate marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ammonia</measure>
    <time_frame>30 Days</time_frame>
    <description>To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Function measured by the Glasgow Coma Scale (GCS)</measure>
    <time_frame>30 Days</time_frame>
    <description>To evaluate the effect of OCR-002 on neurological function in patients with acute liver failure/severe acute liver injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Function measured by the West Haven Criteria (WHC)</measure>
    <time_frame>30 Days</time_frame>
    <description>To evaluate the effect of OCR-002 on neurological function in patients with acute liver failure/severe acute liver injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Function measured by the Orientation log (O-log)</measure>
    <time_frame>30 Days</time_frame>
    <description>To evaluate the effect of OCR-002 on neurological function in patients with acute liver failure/severe acute liver injury</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Acute Liver Failure</condition>
  <condition>Acute Liver Injury</condition>
  <arm_group>
    <arm_group_label>Ornithine Phenylacetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ornithine Phenylacetate is administered intravenously, through a peripheral venous catheter. Each infusion should will be administered over a period of 120 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ornithine phenylacetate</intervention_name>
    <description>Up to 36 patients will be enrolled into 2 groups [~18 with minimal renal dysfunction (Cohort 1) &amp; ~18 w/ comprised renal function (Cohort 2)] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.
The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.
The remaining 12 patients (~6 Cohort 1 &amp; ~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4).</description>
    <arm_group_label>Ornithine Phenylacetate</arm_group_label>
    <other_name>OCR-002</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, ages 18-65 (have not reached their 66th birthday).

          2. Acute liver failure, defined as the development of coagulopathy (International
             normalized ratio [INR] ≥1.5) with encephalopathy in a patient with no prior history of
             liver disease, with onset of symptoms within 28 days of the inciting event. Patients
             may have either a history of acetaminophen overdose (defined as &gt;4 g/day within 7 days
             of presentation) and/or detectable acetaminophen levels in the serum, with a pattern
             of liver function tests typical for acetaminophen toxicity (bilirubin &lt; 10 mg/dL and
             alanine aminotransferase (ALT) ≥1000 IU/L), or a diagnosis of hepatitis A, hepatitis
             B, drug-induced liver injury, autoimmune hepatitis or indeterminate cause based on
             standard criteria.

          3. ALI patients may also be enrolled (those meeting the above criteria plus coagulopathy
             (INR ≥ 2.0) and no evidence of encephalopathy)

          4. Written informed consent from the patient (ALI) or patient's legally authorized
             representative or family member if he/she is considered encephalopathic (ALF).

          5. Ammonia level ≥60 μmol/L at baseline (within 8h prior to T0/initiation of infusion).

          6. Serum creatinine levels as follows:

               1. Cohort 1: Creatinine ≤1.5 mg/dL; and

               2. Cohort 2: Creatinine &gt;1.5 mg/dL and &lt;10mg/dL.

          7. Mean arterial pressure of &gt;65 mmHg.

        Exclusion Criteria:

          1. History of chronic liver disease.

          2. Signs of overt cerebral herniation, or uncontrolled intracranial hypertension by ICP
             monitoring (if applicable).

          3. Evidence of Wilson's disease, alcoholic hepatitis, biliary obstruction, ischemic
             hepatitis, severe acute renal tubular necrosis (ATN) due to shock, or any patient with
             ongoing hypotension.

          4. Significant gastrointestinal bleeding (coffee grounds per nasogastric tube and/or
             melena).

          5. Hemodynamic instability, defined by a mean arterial pressure of &lt;65 mmHg.

          6. Cardiopulmonary complications such as pulmonary edema, aspiration pneumonia, heart
             failure.

          7. QT interval of &gt;500msec at baseline EKG.

          8. Pregnancy.

          9. History of malignancy that has not been cured or any cancer in remission for less than
             1 within the past 5 year. Non-melanoma skin cancers do not preclude participation in
             the trial.

         10. Concomitant administration of drugs known to interfere with renal excretion of
             phenylacetylglutamine or those medications that may induce hyperammonemia such as
             haloperidol, valproic acid and systemic corticosteroids (prohibited during the study).
             Alternative ammonia modifying agents such as lactulose and rifaximin are not
             considered standard of care and are prohibited during the study period.

         11. Any other health condition that would preclude participation in the study in the
             judgment of the principal investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William M Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.utsouthwestern.edu/labs/acute-liver/</url>
    <description>Acute Liver Failure Study Website</description>
  </link>
  <link>
    <url>http://youtu.be/WUKZWx3Qa7U</url>
    <description>Instructional STOP-ALF YouTube Video</description>
  </link>
  <reference>
    <citation>Lee WM. Etiologies of acute liver failure. Semin Liver Dis. 2008 May;28(2):142-52. doi: 10.1055/s-2008-1073114. Review.</citation>
    <PMID>18452114</PMID>
  </reference>
  <reference>
    <citation>Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl. 2004 Jul;10(7):886-97.</citation>
    <PMID>15237373</PMID>
  </reference>
  <reference>
    <citation>Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol. 2009 Sep;6(9):542-53. doi: 10.1038/nrgastro.2009.127. Epub 2009 Aug 4. Review.</citation>
    <PMID>19652652</PMID>
  </reference>
  <reference>
    <citation>Blei AT. Pathogenesis of brain edema in fulminant hepatic failure. Prog Liver Dis. 1995;13:311-30. Review.</citation>
    <PMID>9224508</PMID>
  </reference>
  <reference>
    <citation>Jalan R. Pathophysiological basis of therapy of raised intracranial pressure in acute liver failure. Neurochem Int. 2005 Jul;47(1-2):78-83. Review.</citation>
    <PMID>15927306</PMID>
  </reference>
  <reference>
    <citation>Larsen FS, Wendon J. Prevention and management of brain edema in patients with acute liver failure. Liver Transpl. 2008 Oct;14 Suppl 2:S90-6. doi: 10.1002/lt.21643. Review.</citation>
    <PMID>18825686</PMID>
  </reference>
  <reference>
    <citation>Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology. 1999 Mar;29(3):648-53.</citation>
    <PMID>10051463</PMID>
  </reference>
  <reference>
    <citation>Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J Hepatol. 1999 Oct;31(4):771-6. Review.</citation>
    <PMID>10551405</PMID>
  </reference>
  <reference>
    <citation>Bhatia V, Singh R, Acharya SK. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut. 2006 Jan;55(1):98-104. Epub 2005 Jul 15.</citation>
    <PMID>16024550</PMID>
  </reference>
  <reference>
    <citation>Traber PG, Dal Canto M, Ganger DR, Blei AT. Electron microscopic evaluation of brain edema in rabbits with galactosamine-induced fulminant hepatic failure: ultrastructure and integrity of the blood-brain barrier. Hepatology. 1987 Nov-Dec;7(6):1272-7.</citation>
    <PMID>3679092</PMID>
  </reference>
  <reference>
    <citation>Cordoba J, Gottstein J, Blei AT. Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema. Hepatology. 1996 Oct;24(4):919-23.</citation>
    <PMID>8855198</PMID>
  </reference>
  <reference>
    <citation>Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology. 1999 Sep;30(3):636-40.</citation>
    <PMID>10462368</PMID>
  </reference>
  <reference>
    <citation>Rose C, Michalak A, Pannunzio M, Chatauret N, Rambaldi A, Butterworth RF. Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure. Hepatology. 2000 Apr;31(4):872-7.</citation>
    <PMID>10733542</PMID>
  </reference>
  <reference>
    <citation>Jalan R, Wright G, Davies NA, Hodges SJ. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses. 2007;69(5):1064-9. Epub 2007 Apr 27.</citation>
    <PMID>17467190</PMID>
  </reference>
  <reference>
    <citation>Polson J, Lee WM; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology. 2005 May;41(5):1179-97.</citation>
    <PMID>15841455</PMID>
  </reference>
  <reference>
    <citation>Sterling RK, Luketic VA, Sanyal AJ, Shiffman ML. Treatment of fulminant hepatic failure with intravenous prostaglandin E1. Liver Transpl Surg. 1998 Sep;4(5):424-31.</citation>
    <PMID>9724481</PMID>
  </reference>
  <reference>
    <citation>O'Grady JG, Gimson AE, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology. 1988 May;94(5 Pt 1):1186-92.</citation>
    <PMID>3280388</PMID>
  </reference>
  <reference>
    <citation>Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology. 2004 Nov;127(5):1338-46.</citation>
    <PMID>15521003</PMID>
  </reference>
  <reference>
    <citation>Stravitz RT, Larsen FS. Therapeutic hypothermia for acute liver failure. Crit Care Med. 2009 Jul;37(7 Suppl):S258-64. doi: 10.1097/CCM.0b013e3181aa5fb8. Review.</citation>
    <PMID>19535956</PMID>
  </reference>
  <reference>
    <citation>Randomised trial of steroid therapy in acute liver failure. Report from the European Association for the Study of the Liver (EASL). Gut. 1979 Jul;20(7):620-3.</citation>
    <PMID>385456</PMID>
  </reference>
  <reference>
    <citation>Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, Sharma BC, Sarin SK. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007 Jan;45(1):97-101.</citation>
    <PMID>17187417</PMID>
  </reference>
  <reference>
    <citation>Ichai P, Duclos-Vallée JC, Guettier C, Hamida SB, Antonini T, Delvart V, Saliba F, Azoulay D, Castaing D, Samuel D. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007 Jul;13(7):996-1003.</citation>
    <PMID>17370335</PMID>
  </reference>
  <reference>
    <citation>Makin AJ, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology. 1995 Dec;109(6):1907-16.</citation>
    <PMID>7498656</PMID>
  </reference>
  <reference>
    <citation>Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiødt FV, Ostapowicz G, Shakil AO, Lee WM; Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005 Dec;42(6):1364-72.</citation>
    <PMID>16317692</PMID>
  </reference>
  <reference>
    <citation>Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern TJ 2nd, Murray NG, McCashland T, Reisch JS, Robuck PR; Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009 Sep;137(3):856-64, 864.e1. doi: 10.1053/j.gastro.2009.06.006. Epub 2009 Jun 12. Erratum in: Gastroenterology. 2013 Sep;145(3):695. Dosage error in article text.</citation>
    <PMID>19524577</PMID>
  </reference>
  <reference>
    <citation>Liou IW, Larson AM. Role of liver transplantation in acute liver failure. Semin Liver Dis. 2008 May;28(2):201-9. doi: 10.1055/s-2008-1073119. Review.</citation>
    <PMID>18452119</PMID>
  </reference>
  <reference>
    <citation>Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, Blei AT, Fontana RJ, McGuire BM, Rossaro L, Smith AD, Lee WM; Acute Liver Failure Study Group. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med. 2007 Nov;35(11):2498-508.</citation>
    <PMID>17901832</PMID>
  </reference>
  <reference>
    <citation>Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology. 2009 Jun;136(7):2159-68. doi: 10.1053/j.gastro.2009.02.050.</citation>
    <PMID>19505424</PMID>
  </reference>
  <reference>
    <citation>Jalan R, Lee WM. Treatment of hyperammonemia in liver failure: a tale of two enzymes. Gastroenterology. 2009 Jun;136(7):2048-51. doi: 10.1053/j.gastro.2009.04.016. Epub 2009 May 3.</citation>
    <PMID>19409290</PMID>
  </reference>
  <reference>
    <citation>Davies NA, Wright G, Ytrebø LM, Stadlbauer V, Fuskevåg OM, Zwingmann C, Davies DC, Habtesion A, Hodges SJ, Jalan R. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology. 2009 Jul;50(1):155-64. doi: 10.1002/hep.22897.</citation>
    <PMID>19437490</PMID>
  </reference>
  <reference>
    <citation>Ytrebø LM, Kristiansen RG, Maehre H, Fuskevåg OM, Kalstad T, Revhaug A, Cobos MJ, Jalan R, Rose CF. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology. 2009 Jul;50(1):165-74. doi: 10.1002/hep.22917.</citation>
    <PMID>19554542</PMID>
  </reference>
  <reference>
    <citation>Zimmerman L, Jörnvall H, Bergström J. Phenylacetylglutamine and hippuric acid in uremic and healthy subjects. Nephron. 1990;55(3):265-71.</citation>
    <PMID>2370926</PMID>
  </reference>
  <reference>
    <citation>Novack, T. (2000). The Orientation Log. The Center for Outcome Measurement in Brain Injury. http://www.tbims.org/combi/olog</citation>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>William Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ornithine</keyword>
  <keyword>phenylacetate</keyword>
  <keyword>acetaminophen toxicity</keyword>
  <keyword>acute liver failure</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>autoimmune hepatitis</keyword>
  <keyword>drug-induced liver injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylacetic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data for the overall study will be shared once the study is completed.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>May 4, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

